Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1958 3
1966 1
1967 2
1970 1
1971 4
1972 1
1973 1
1974 1
1975 9
1976 5
1977 12
1978 9
1979 11
1980 5
1981 11
1982 18
1983 17
1984 19
1985 23
1986 28
1987 40
1988 66
1989 82
1990 95
1991 103
1992 121
1993 142
1994 164
1995 273
1996 278
1997 405
1998 433
1999 409
2000 515
2001 548
2002 513
2003 591
2004 584
2005 640
2006 662
2007 717
2008 759
2009 815
2010 918
2011 1002
2012 1042
2013 1199
2014 1708
2015 2117
2016 2206
2017 2388
2018 2564
2019 2673
2020 3341
2021 3221
2022 2758
2023 2425
2024 1090

Text availability

Article attribute

Article type

Publication date

Search Results

35,930 results

Results by year

Filters applied: . Clear all
Page 1
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Sniffen JC, et al. PLoS One. 2018 Dec 26;13(12):e0209205. doi: 10.1371/journal.pone.0209205. eCollection 2018. PLoS One. 2018. PMID: 30586435 Free PMC article.
We graded the strength of the evidence for probiotics having multiple, randomized controlled trials and developed a guide for the practical selection of current probiotic products for specific uses. ...CONCLUSION: The choice of an appropriate probiotic is multi-factored, b …
We graded the strength of the evidence for probiotics having multiple, randomized controlled trials and developed a guide for the pra …
Autophagy and disease.
Thorburn A. Thorburn A. J Biol Chem. 2018 Apr 13;293(15):5425-5430. doi: 10.1074/jbc.R117.810739. Epub 2017 Nov 30. J Biol Chem. 2018. PMID: 29191833 Free PMC article. Review.
Importantly, these connections are already being exploited to treat patients with dozens of clinical trials that aim to manipulate autophagy to treat (or prevent) disease. ...
Importantly, these connections are already being exploited to treat patients with dozens of clinical trials that aim to manipulate au …
Discontinuing beta-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Makhloufi S, Mellon G, de Lastours V, Bouchand F, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Renaud B, Perronne C, Claessens YE, Labarère J, Bedos JP, Aegerter P, Crémieux AC; Pneumonia Short Treatment (PTC) Study Group. Dinh A, et al. Lancet. 2021 Mar 27;397(10280):1195-1203. doi: 10.1016/S0140-6736(21)00313-5. Lancet. 2021. PMID: 33773631 Clinical Trial.
We aimed to assess the need for an additional 5-day course of beta-lactam therapy among patients with community-acquired pneumonia who were stable after 3 days of treatment. METHODS: We did this double-blind, randomised, placebo-controlled, non-inferiority trial (th …
We aimed to assess the need for an additional 5-day course of beta-lactam therapy among patients with community-acquired pneumonia who were …
Progress in infectious disease and immunology.
Zuccotti G, Fontanarosa PB. Zuccotti G, et al. JAMA. 2011 Apr 13;305(14):1486-7. doi: 10.1001/jama.2011.452. JAMA. 2011. PMID: 21486983 No abstract available.
Monoclonal antibody-based therapies for bacterial infections.
Motley MP, Banerjee K, Fries BC. Motley MP, et al. Curr Opin Infect Dis. 2019 Jun;32(3):210-216. doi: 10.1097/QCO.0000000000000539. Curr Opin Infect Dis. 2019. PMID: 30950853 Free PMC article. Review.
PURPOSE OF REVIEW: This review highlights recent developments in the development of monoclonal antibodies to treat bacterial disease, including preclinical advances and the status of current clinical trials. RECENT FINDINGS: Monoclonal antibody (mAb) therapy is becoming in …
PURPOSE OF REVIEW: This review highlights recent developments in the development of monoclonal antibodies to treat bacterial disease, includ …
How the Cluster-randomized Trial "Works".
Hurley JC. Hurley JC. Clin Infect Dis. 2020 Jan 2;70(2):341-346. doi: 10.1093/cid/ciz554. Clin Infect Dis. 2020. PMID: 31260511
Cluster-randomized trials (CRTs) are able to address research questions that randomized controlled trials (RCTs) of individual patients cannot answer. Of great interest for infectious disease physicians and infection control practitioners are research …
Cluster-randomized trials (CRTs) are able to address research questions that randomized controlled trials (RCTs) of individual …
Improving vaccine trials in infectious disease emergencies.
Lipsitch M, Eyal N. Lipsitch M, et al. Science. 2017 Jul 14;357(6347):153-156. doi: 10.1126/science.aam8334. Science. 2017. PMID: 28706038 Free PMC article. Review.
Unprecedented global effort is under way to facilitate the testing of countermeasures in infectious disease emergencies. Better understanding of the various options for trial design is needed in advance of outbreaks, as is preliminary global agreement on the …
Unprecedented global effort is under way to facilitate the testing of countermeasures in infectious disease emergencies. Bette …
Hepatitis E virus.
Khuroo MS, Khuroo MS. Khuroo MS, et al. Curr Opin Infect Dis. 2008 Oct;21(5):539-43. doi: 10.1097/QCO.0b013e32830ee08a. Curr Opin Infect Dis. 2008. PMID: 18725805 Review.
PURPOSE OF REVIEW: Hepatitis E is an emerging infectious disease. This review will focus on recent advances in the zoonotic transmission, global distribution and control of hepatitis E. ...A recombinant hepatitis E vaccine has been evaluated in a phase 2, randomi …
PURPOSE OF REVIEW: Hepatitis E is an emerging infectious disease. This review will focus on recent advances in the zoonotic tr …
Nanoparticles in clinical trials of COVID-19: An update.
Rauf A, Abu-Izneid T, Khalil AA, Hafeez N, Olatunde A, Rahman M, Semwal P, Al-Awthan YS, Bahattab OS, Khan IN, Khan MA, Sharma R. Rauf A, et al. Int J Surg. 2022 Aug;104:106818. doi: 10.1016/j.ijsu.2022.106818. Epub 2022 Aug 8. Int J Surg. 2022. PMID: 35953020 Free PMC article. Review.
Once the World Health Organization (WHO) declared the COVID-19 (Coronavirus Infectious Disease-19) outbreak to be pandemic, massive efforts have been launched by researchers around the globe to combat this emerging infectious disease. ...Many of these …
Once the World Health Organization (WHO) declared the COVID-19 (Coronavirus Infectious Disease-19) outbreak to be pandemic, ma …
Enterococcus, an emerging pathogen.
Tailor SA, Bailey EM, Rybak MJ. Tailor SA, et al. Ann Pharmacother. 1993 Oct;27(10):1231-42. doi: 10.1177/106002809302701014. Ann Pharmacother. 1993. PMID: 8251694 Review.
Information also was acquired from abstracts, personal communication with infectious disease specialists with active research in the area of enterococcal infection, and conference proceedings. ...DATA EXTRACTION: Studies were evaluated by their methodologic strength …
Information also was acquired from abstracts, personal communication with infectious disease specialists with active research …
35,930 results
You have reached the last available page of results. Please see the User Guide for more information.